{
    "Trade/Device Name(s)": [
        "Spartan RX CYP2C19 System",
        "Spartan RX CYP2C19 Assay",
        "Spartan RX CYP2C19 Platform"
    ],
    "Submitter Information": "Spartan Bioscience Inc.",
    "510(k) Number": "K123891",
    "Predicate Device Reference 510(k) Number(s)": [
        "K101683"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NTI",
        "NSU"
    ],
    "Summary Letter Date": "August 12, 2013",
    "Summary Letter Received Date": "July 3, 2013",
    "Submission Date": "June 28, 2013",
    "Regulation Number(s)": [
        "21 CFR 862.3360",
        "21 CFR 862.2570"
    ],
    "Regulation Name(s)": [
        "Drug metabolizing enzyme genotyping system",
        "Instrumentation for clinical multiplex test systems"
    ],
    "Analyte Class(es)": [
        "genetic molecular",
        "chemistry",
        "toxicology"
    ],
    "Analyte(s)": [
        "CYP2C19 *2",
        "CYP2C19 *3",
        "CYP2C19 *17"
    ],
    "Specimen Type(s)": [
        "DNA from buccal cells"
    ],
    "Specimen Container(s)": [
        "Buccal swab",
        "Reagent tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Spartan RX Analyzer",
        "Spartan RX CYP2C19 Platform",
        "Netbook",
        "Printer",
        "Barcode scanner"
    ],
    "Method(s)/Technology(ies)": [
        "Polymerase Chain Reaction (PCR)",
        "Fluorescent probe detection",
        "Automated DNA extraction and amplification"
    ],
    "Methodologies": [
        "Genotyping",
        "PCR-based amplification",
        "Fluorescent signal detection and analysis"
    ],
    "Submission Type(s)": [
        "System",
        "Assay",
        "Analyzer",
        "Platform",
        "Sample collection device",
        "Reagent",
        "Accessory",
        "Consumable"
    ],
    "Document Summary": "FDA 510(k) summary for Spartan RX CYP2C19 System using PCR genotyping for CYP2C19 *2, *3, and *17 alleles from buccal swab DNA",
    "Indications for Use Summary": "Aids clinicians in determining therapeutic strategies for drugs metabolized by CYP2C19, specifically for *2, *3, and *17 alleles, using genotype results from buccal swab DNA on the Spartan RX CYP2C19 System; not for predicting drug response or non-response",
    "fda_folder": "Toxicology"
}